RECURRENT WHO GRADE 2 GLIOMA
Clinical trials for RECURRENT WHO GRADE 2 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE 2 GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE 2 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for kids with brain cancer
Disease control OngoingThis study tests whether adding vinblastine to selumetinib works better than selumetinib alone for children and young adults with a slow-growing brain tumor (low-grade glioma) that has come back or is not responding to treatment. About 300 participants aged 2 to 25 will receive e…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:46 UTC
-
Precision drug ivosidenib tested in kids with tough IDH1 cancers
Disease control OngoingThis study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New hope for kids with rare cancers: targeted drug takes aim at HRAS gene
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New targeted drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients with advanced solid…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC